Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in PK/PD Bridging for ADCs & Bispecifics
Accelerate Your Complex Biologic Development! Are you currently facing challenges in precisely predicting the clinical safety and optimal dose of complex biotherapeutics like ADCs and Bispecifics due to nonlinear pharmacokinetics and unpredictable toxicity? Creative Biolabs' NHP Translational PK/PD Platform helps you achieve regulatory compliance and streamline clinical trial processes by providing robust, predictive data on multi-analyte PK, Target-Mediated Drug Disposition, and critical safety risks through quantitative, Model-Informed Drug Development methodologies.
NHP models are crucial for robust translational pharmacology in predicting multi-analyte PK
Complex biotherapeutics like ADCs and Bispecifics require rigorous translational pharmacology to predict multi-analyte PK, off-target toxicity, and dose-response in humans. NHP models provide the essential bridge.
Overview of NHP Applications
What Are Our Research Areas?
Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies represent two of the most promising yet pharmacologically complex therapeutic modalities. For ADCs, the challenge lies in managing a three-component system: the Total Antibody (governing half-life via FcRn), the Conjugated Drug (the efficacy driver), and the highly toxic Free Payload (the primary safety concern). Bispecifics, engineered to engage two distinct targets, introduce unique complexities in binding kinetics and Target-Mediated Drug Disposition (TMDD). Developing a successful program requires a quantitative understanding of these nonlinear, multi-analyte interactions and their direct impact on clinical safety and efficacy—a field known as Translational PK/PD.
Why Choose Us?
NHPs are uniquely positioned to bridge preclinical and clinical data for ADCs and Bispecifics, serving as the required non-rodent species for IND-enabling studies. Creative Biolabs leverages these advantages to de-risk your program:
- Genetic and Immunological Similarities: NHPs possess high homology with humans in key receptors (like the FcRn, which dictates IgG/ADC half-life) and immune system components, allowing for relevant assessment of Anti-Drug Antibody (ADA) risk and subsequent accelerated clearance.
- Clinical Translational Relevance: Only NHP models accurately capture the complex, non-linear pharmacokinetics seen with high-affinity biotherapeutics, enabling reliable prediction of human equivalent dose.
- Multi-Analyte Profile Assessment: NHPs allow for the simultaneous monitoring of Total Ab, Conjugated Drug, and Free Payload, providing the necessary data triangulation for linker stability analysis and toxicity prediction.
Fig.1 Characteristics of antibodies influencing PK properties.1
Key Applications
Creative Biolabs utilizes NHP models to execute critical studies that directly address the core translational challenges of ADCs and Bispecifics:
- Validate Multi-Analyte PK and Free Payload Risk: NHPs allow for the precise, longitudinal study of the Total Antibody, intact ADC, and liberated Free Payload. This provides crucial data on linker stability, deconjugation rate, and the systemic exposure of the toxic payload—informing the safety margin and mitigating unpredictable hematological adverse events.
- Model Non-Linear Clearance and TMDD: Due to high target affinity, both ADCs and Bispecifics frequently exhibit TMDD. NHP dose-escalation studies are essential for quantifying the saturation of clearance pathways, enabling the development of accurate PK/PD Models for precise FIH dose prediction.
- Assess Immunogenicity (ADA) and Off-Target Safety: NHPs serve as the primary model to predict immune responses (ADA formation) that could accelerate drug clearance. Furthermore, they are used to test for off-target binding—a significant risk factor that can lead to unexpected toxicity and poor PK, necessitating early de-risking.
- Delineate Mechanisms-of-Action for Dual-Targeting Bispecifics: For Bispecifics, NHPs enable the simultaneous assessment of receptor occupancy (RO) on two targets in relevant tissues, confirming the bridging mechanism, pathway engagement, and predicting the synergistic therapeutic effect in a clinically relevant context.
How Do Creative Biolabs Support Your Projects?
Creative Biolabs' comprehensive service portfolio is aligned with the critical data requirements for developing complex biotherapeutics, ensuring full support for your Model-Informed Drug Development strategy. Inquire now to discuss custom study design.
| Service Capability | Corresponding Application Area |
| In Vivo PK Studies | Provides raw PK data in NHPs for Total Ab, Conjugated Drug, and Free Payload. |
| PK/PD Modeling & Simulation | Utilizes NHP data to build models, incorporating TMDD, for optimal human dose prediction. |
| In Vivo Toxicology Studies | Essential for establishing the safety margin and characterizing the dose-limiting hematological toxicities driven by the free payload. |
| PK/TK Sample Analysis | Precise, regulatory-grade bioanalysis of Total Ab, intact ADC, and Free Payload from NHP samples. |
Translational Impact
The use of NHP models is the cornerstone of successful ADC and Bispecific translation, directly impacting your regulatory outcome and market timeline. By accurately modeling TMDD and the kinetics of free payload release in NHPs, Creative Biolabs enables the early establishment of a robust human safety margin and a predictive exposure-response relationship. Clients utilizing our integrated NHP PK/PD modeling typically see a reduction in the duration of their clinical dose-escalation phase, significantly accelerating the path to Phase II. This enhanced predictability drastically reduces the risk of IND failure due to unforeseen PK complexities or dose-limiting toxicities.
Frequently Asked Questions
Q: How does NHP testing specifically help me manage the complexity of the three-analyte PK for ADCs?
A: NHPs allow us to run bioanalytical methods that simultaneously quantify the three critical analytes (Total Ab, Conjugated Drug, and Free Payload) in a physiologically relevant system. This data feeds directly into our modeling to accurately determine the rate of in vivo deconjugation, giving you a precise measure of linker stability and the actual systemic exposure to the toxic payload—the key driver of clinical risk. We encourage you to contact us to see an example of our multi-analyte PK/PD reports.
Q: Since my bispecific antibody is high affinity, how do your NHP studies account for the non-linear clearance caused by TMDD?
A: High-affinity biotherapeutics are prone to TMDD, which makes PK non-linear. Our NHP studies are designed with ascending single and multiple doses across a broad range to explicitly capture the TMDD profile. We then integrate this non-linear data into our PK/PD Modeling & Simulation to predict the target-saturating dose in humans and determine the optimal dosing interval and amount.
Q: What kind of data can I expect regarding the immunogenicity (ADA) risk, and how quickly can Creative Biolabs provide it?
A: We provide comprehensive immunogenicity testing, including both Anti-Drug Antibody (ADA) screening assays and confirmatory NAb assays, all conducted in NHP models. These assays are crucial for predicting the risk of accelerated clearance in humans. Turnaround times vary depending on the study design and required NAb complexity, but we prioritize providing rapid and high-quality data to inform your regulatory submission strategy. Reach out to our bioanalysis team for detailed logistics.
Q: What are the specific precautions Creative Biolabs takes when dealing with the highly potent payloads of ADCs in NHP studies?
A: Safety is paramount. We adhere to stringent safety protocols and handle all ADC and free payload materials under highly controlled conditions. Our NHP study designs, especially toxicology studies, incorporate refined dosing and monitoring to ensure animal welfare while accurately capturing the toxicity profile, particularly the sensitive hematological endpoints, providing reliable data on the Highest Non-Severely Toxic Dose.
Contact Us
Creative Biolabs is your trusted partner for navigating the complexity of Antibody-Drug Conjugate and Bispecific development. By offering integrated NHP pharmacology and advanced multi-analyte bioanalysis, we provide the predictive power necessary for optimal dose selection and de-risking clinical trials. To receive a detailed quote, discuss custom study designs, or learn more about how our NHP platform can accelerate your IND submission, please contact us.
Reference
- CLiu, Liming. "Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins." Protein & cell vol. 9,1 (2018): 15-32. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1007/s13238-017-0408-4